Edition:
United Kingdom

Alder Biopharmaceuticals Inc (ALDR.OQ)

ALDR.OQ on NASDAQ Stock Exchange Global Market

15.50USD
23 May 2018
Change (% chg)

$0.45 (+2.99%)
Prev Close
$15.05
Open
$15.00
Day's High
$15.55
Day's Low
$15.00
Volume
138,464
Avg. Vol
258,519
52-wk High
$20.00
52-wk Low
$8.68

Chart for

About

Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated... (more)

Overall

Beta: 2.62
Market Cap(Mil.): $863.35
Shares Outstanding(Mil.): 67.71
Dividend: --
Yield (%): --

Financials

  ALDR.OQ Industry Sector
P/E (TTM): -- 84.06 32.75
EPS (TTM): -5.14 -- --
ROI: -76.39 1.57 14.38
ROE: -76.45 2.43 16.07

BRIEF-Alder Biopharmaceuticals Reports Q1 Loss Per Share Of $1.73

* ALDER BIOPHARMACEUTICALS® REPORTS FIRST QUARTER 2018 FINANCIAL AND OPERATING RESULTS

08 May 2018

BRIEF-Alder Biopharmaceuticals Appoints Jeremy Green To Its Board Of Directors

* ALDER BIOPHARMACEUTICALS APPOINTS JEREMY GREEN TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

26 Apr 2018

BRIEF-Alder Biopharmaceuticals - New Data Demonstrated Eptinezumab Increased Migraine-Free Intervals In Patients With Episodic Migraine

* ALDER BIOPHARMACEUTICALS® NEW DATA DEMONSTRATED EPTINEZUMAB INCREASED MIGRAINE-FREE INTERVALS (UP TO 32.5 DAYS) AND IMPROVED QUALITY-OF-LIFE OUTCOMES IN PATIENTS WITH EPISODIC MIGRAINE

25 Apr 2018

BRIEF-Alder Biopharmaceuticals Presents New 12-Month Data Of Eptinezumab In Promise 1 Phase 3 Trial

* ALDER BIOPHARMACEUTICALS® PRESENTS NEW 12-MONTH DATA OF EPTINEZUMAB IN PROMISE 1 PHASE 3 TRIAL SHOWING LONG-TERM REDUCTION IN EPISODIC MIGRAINE

24 Apr 2018

BRIEF-Alder Biopharmaceuticals Inc To Present New Phase 3 Migraine Prevention Data For Eptinezumab

* ALDER BIOPHARMACEUTICALS INC - TO PRESENT NEW PHASE 3 MIGRAINE PREVENTION DATA FOR EPTINEZUMAB AT 70TH ANNUAL AMERICAN ACADEMY OF NEUROLOGY MEETING Source text for Eikon: Further company coverage:

18 Apr 2018

BRIEF-Alder Biopharmaceuticals Appoints Erin Lavelle To Newly Created Role Of Chief Operating Officer

* ALDER BIOPHARMACEUTICALS® APPOINTS ERIN LAVELLE TO NEWLY CREATED ROLE OF CHIEF OPERATING OFFICER Source text for Eikon: Further company coverage:

16 Apr 2018

BRIEF-Redmile Group Reports 9.99 Pct Stake In Alder Biopharmaceuticals

* REDMILE GROUP, LLC REPORTS 9.99 PERCENT STAKE IN ALDER BIOPHARMACEUTICALS INC AS OF MARCH 23, 2018 - SEC FILING‍​ Source text: (https://bit.ly/2HZWQqw)

23 Mar 2018

BRIEF-Alder Biopharma Q4 Loss Per Share $0.80

* ALDER BIOPHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL AND OPERATING RESULTS

26 Feb 2018

BRIEF-Alder Biopharmaceuticals Enters Into European Patent Settlement, Global License Agreement With Teva

* ALDER BIOPHARMACEUTICALS® ENTERS INTO EUROPEAN PATENT SETTLEMENT AND GLOBAL LICENSE AGREEMENT WITH TEVA IN THE FIELD OF ANTI-CGRP-BASED THERAPY

08 Jan 2018

BRIEF-Alder Announces $250 Million Committed Equity Financing

* ALDER BIOPHARMACEUTICALS INC - INVESTORS TO PURCHASE UP TO $250 MILLION OF NON-VOTING CLASS A PREFERRED STOCK DURING 3-YEAR TERM OF AGREEMENT

08 Jan 2018

Competitors

Earnings vs. Estimates